^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MET overexpression + HER-2 overexpression

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    2064; 4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    3years
    The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer. (PubMed, Front Oncol)
    MET expression was examined immunohistochemically before and after treatment in 122 patients with unresectable or recurrent GC, and was evaluated according to H-score or the scoring criteria used in the MetMAb trial. MET expression is altered post chemotherapy and MET status should be evaluated in real-time. Both MET and pMET expressions might need to be considered for patients suitable for volitinib treatment.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    HER-2 overexpression • MET amplification • MET overexpression • MET expression • MET overexpression + HER-2 overexpression
    |
    Orpathys (savolitinib) • onartuzumab (RG3638)